Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Amgen Inc (AMGN)

Amgen Inc (AMGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 138,943,984
  • Shares Outstanding, K 594,184
  • Annual Sales, $ 23,747 M
  • Annual Income, $ 8,394 M
  • 60-Month Beta 1.12
  • Price/Sales 5.83
  • Price/Cash Flow 12.88
  • Price/Book 12.66

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 19 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 3.43
  • Number of Estimates 11
  • High Estimate 3.83
  • Low Estimate 3.20
  • Prior Year 3.42
  • Growth Rate Est. (year over year) +0.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
213.55 +9.61%
on 11/14/19
235.80 -0.73%
on 12/02/19
+13.38 (+6.06%)
since 11/11/19
3-Month
188.78 +24.00%
on 10/02/19
235.80 -0.73%
on 12/02/19
+38.24 (+19.53%)
since 09/11/19
52-Week
166.30 +40.76%
on 05/15/19
235.80 -0.73%
on 12/02/19
+37.90 (+19.32%)
since 12/11/18

Most Recent Stories

More News
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

The biotech sector witnesses pipeline updates from the annual ASH meet.

GILD : 67.46 (+0.57%)
AMGN : 234.46 (+0.27%)
BLUE : 88.32 (+3.07%)
FATE : 19.33 (+2.22%)
VRTX : 222.39 (+0.96%)
REGN : 376.10 (+2.29%)
SAGE : 67.50 (+6.65%)
Biotech ETFs Hit New Highs on Deal Activities

Following the new deals in the healthcare space, a few biotech ETFs hit new highs.

AGN : 186.75 (+0.61%)
SNY : 48.65 (+1.16%)
ABBV : 86.90 (+0.39%)
MRK : 89.16 (+0.07%)
BMY : 62.41 (+0.52%)
IBB : 119.73 (-0.31%)
CNCR : 23.36 (+0.43%)
BBC : 35.91 (-0.28%)
XBI : 94.88 (-0.68%)
SBIO : 42.35 (-0.26%)
THOR : 67.80 (unch)
AMGN : 234.46 (+0.27%)
CELG : 108.24 (+0.10%)
ARQL : 20.01 (+0.30%)
G : 40.53 (-0.15%)
Global Osteoporosis Drugs Market Insights 2019-2025 Featuring Profiles of Amgen, Novartis, Eli Lilly & Company, Pfizer, and Radius Health

The "Osteoporosis Drugs Market - By Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulator, RANK Ligand Inhibitors, Biosimilars, and Others), By Regions (North...

AMGN : 234.46 (+0.27%)
LLY : 120.32 (-0.27%)
NVS : 92.69 (-0.12%)
RDUS : 22.28 (-3.63%)
Healthpeak Amends & Extends Lease With Amgen in San Francisco

Healthpeak's (PEAK) lease amendment and extension with Amgen at the Britannia Oyster Point of the former offers flexibility in addressing lease-expiration issue at this property.

AMGN : 234.46 (+0.27%)
CUZ : 40.29 (-0.44%)
PLD : 90.91 (-0.25%)
PEAK : 33.44 (-0.62%)
Amgen Data From Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) To Be Presented During Late-Breaking Session At American Society Of Hematology Annual Meeting

Amgen (NASDAQ:AMGN) today announced additional results from the primary analysis of the Phase 3 CANDOR study evaluating KYPROLIS® (carfilzomib) in combination with dexamethasone and DARZALEX® (daratumumab)...

AMGN : 234.46 (+0.27%)
Healthpeak(TM) Announces Lease Amendment and Extension with Amgen in South San Francisco

Healthpeak Properties, Inc. (NYSE: PEAK) announced today that it has executed a lease amendment and extension with Amgen at Healthpeak's Britannia Oyster Point ("BOP") campus in South San Francisco. The...

AMGN : 234.46 (+0.27%)
PEAK : 33.44 (-0.62%)
Beyond Cholesterol: Landmark deCODE Study Elucidates Role of Lipoprotein(a) as Major Risk Factor for Heart Disease

Scientists at deCODE genetics and colleagues from the National University Hospital in Iceland today present the largest-scale study to date of the role and public health impact of Lipoprotein(a) as a risk...

AMGN : 234.46 (+0.27%)
Amgen Gets FDA Approval for J&J/Merck's Remicade Biosimilar

FDA gives nod to Amgen's (AMGN) Avsola (ABP 710), a biosimilar of J&J's blockbuster rheumatoid arthritis drug, Remicade.

PFE : 38.24 (-0.62%)
MRK : 89.16 (+0.07%)
JNJ : 141.24 (+0.89%)
AMGN : 234.46 (+0.27%)
Amgen Selects Location For R&D Facility In The South San Francisco Biotechnology Hub

Amgen (NASDAQ:AMGN) today announced the signing of a lease with BioMed Realty for a new 240,000-square-foot Leadership in Energy and Environmental Design (LEED) candidate facility in the Gateway of Pacific...

AMGN : 234.46 (+0.27%)
BioMed Realty Welcomes Amgen to Its Gateway of Pacific Campus

--- BioMed Realty Continues to Support California's Life Science Industry Growth with $2.6 Billion Capital Commitments in Last Four Years

AMGN : 234.46 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching overbought territory. Be watchful of a trend reversal.

See More Share

Trade AMGN with:

Business Summary

Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science's promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice...

See More

Key Turning Points

2nd Resistance Point 237.10
1st Resistance Point 235.47
Last Price 234.46
1st Support Level 231.86
2nd Support Level 229.88

See More

52-Week High 235.80
Last Price 234.46
Fibonacci 61.8% 209.25
Fibonacci 50% 201.05
Fibonacci 38.2% 192.85
52-Week Low 166.30

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar